rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ACAD
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Oppenheimer lowers Acadia Pharmaceuticals price target on pipeline outlook
      15h agoInvesting.comACAD
      ACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue Surge
      Nov 18Yahoo FinanceACAD
      Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG) and ACADIA Pharmaceuticals (ACAD)

      Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.

      Nov 11The Globe and MailACADISRG
      Acadia gains after oral arguments in Nuplazid patent row (ACAD)

      Acadia Pharmaceuticals (ACAD) stock gains as an appeal court hears oral arguments regarding a patent dispute related to its lead drug, Nuplazid. Read more here.

      Nov 10Seeking AlphaACAD
      Acadia Pharmaceuticals Fell While Sales Rose
      Nov 10Yahoo FinanceACAD
      Acadia Pharmaceuticals (ACAD) Stock Still Looks Like A Bargain Today
      Nov 10Yahoo FinanceACAD
      Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
      Nov 10Yahoo FinanceACAD
      Acadia Pharmaceuticals (ACAD) Cuts 2026 R And D Guidance, Is It Still 46% Undervalued?
      Nov 10Yahoo FinanceACAD
      Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
      Nov 9Yahoo FinanceACAD
      Acadia Pharmaceuticals stock hits 52-week low at 18.24 USD
      Nov 9Investing.comACAD
      Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
      Nov 6Yahoo FinanceACADACHC
      Acadia Pharmaceuticals Sees Continued Daybue Momentum in Q3, RBC Says
      Nov 5Yahoo FinanceACAD
      RBC raises Acadia Pharmaceuticals stock price target on Daybue growth
      Nov 5Investing.comACAD
      ACADIA Pharmaceuticals Inc (ACAD) Q3 2026 Earnings Call Highlights: Record Debut Sales and ...
      Nov 5Yahoo FinanceACAD
      Acadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue Estimates
      Nov 4Yahoo FinanceACADACHC
      ACADIA Pharmaceuticals Q3 2026 Earnings Call Transcript
      Nov 4BenzingaACAD
      Acadia: Q3 Earnings Snapshot
      Nov 4Yahoo FinanceACAD
      Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
      Nov 4Yahoo FinanceACAD
      Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
      Oct 28Yahoo FinanceACADACHCUBS
      Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline

      Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Oct 28Yahoo FinanceACAD
      Acadia Pharmaceuticals announces retirement of R&D head, names interim consultant
      Oct 23Investing.comACAD
      Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
      Oct 21Yahoo FinanceACAD
      ACADIA Pharmaceuticals Shares Fall After UBS Downgrade
      Oct 13Yahoo FinanceACAD
      Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), ACADIA Pharmaceuticals (ACAD) and Insmed (INSM)

      Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailACADINSMPFE
      Acadia Pharmaceuticals stock hits 52-week low at 19.01 USD
      Oct 13Investing.comACAD
      UBS Downgrades ACADIA Pharmaceuticals to Neutral From Buy, $23 Price Target

      ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $31.95, a

      Oct 13Yahoo FinanceACAD
      Acadia Healthcare Announces Date for Third Quarter 2026 Earnings Release
      Oct 13Yahoo FinanceACADACHC
      Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Assembly Biosciences (ASMB)

      Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailACADASMB
      RBC Trims Price Target on ACADIA Pharmaceuticals to $36 From $37, Keeps Outperform Rating
      Oct 8Yahoo FinanceACAD
      Acadia Pharmaceuticals (ACAD) Secures Patent And Phase 2 Progress, Is It 38% Below Fair Value?

      Acadia Pharmaceuticals (ACAD) just stacked two key clinical milestones: a fresh USPTO Notice of Allowance extending potential trofinetide protection to 2041 and Phase 2 RADIANT data guiding remlifanserin into Phase 3 for Alzheimer’s disease psychosis. Despite the fresh patent progress and Phase 2 readout, Acadia Pharmaceuticals’ share price has retreated, with a 30-day share price return down 28.23% and year-to-date share price return down 23.51%, while the 5-year total shareholder return of...

      Oct 6Yahoo FinanceACAD
      RBC Capital reiterates Acadia Pharmaceuticals stock rating on patent developments
      Oct 5Investing.comACAD
      Why is ACADIA Pharmaceuticals stock climbing today?
      Oct 5Investing.comACAD
      Acadia Pharmaceuticals stock hits 52-week low at $19.66
      Oct 1Investing.comACAD
      Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041

      Detailed price information for Aldeyra Therapeu (ALDX-Q) from The Globe and Mail including charting and trades.

      Sep 29The Globe and MailACAD
      Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent
      Sep 28Yahoo FinanceACAD
      Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

      SAN DIEGO, September 28, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled "Methods and Compositions for Treatment of Rett Syndrome." The Notice of Allowance indicates that the USPTO has determined that the application meets the requirements for patentability, and the patent is expected to issue following completion of standard administrati

      Sep 28Yahoo FinanceACAD
      Acadia Pharmaceuticals stock price target lowered to $33 by H.C. Wainwright
      Sep 28Investing.comACAD
      3 Stocks Put Traders Are Targeting Today: AMTX, ACAD, REZI
      Sep 28Yahoo FinanceACAD
      Raymond James Downgrades Acadia Healthcare to Outperform From Strong Buy
      Sep 28Yahoo FinanceACADACHC
      Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop

      Acadia Pharmaceuticals has seen its share price fall sharply over the past month, and that pullback is pushing investors to ask whether the current valuation still lines up with what the business is earning today. With the stock under pressure and expectations around its drug pipeline shifting, the key issue is how much of those earnings are already reflected in the price. The share price is down 29.0% over the past month. That puts fresh focus on whether recent weakness has moved Acadia...

      Sep 27Yahoo FinanceACAD
      BMO Capital Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)

      Tipranks Press Release.

      Sep 26The Globe and MailACAD
      Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Kyverna Therapeutics, Inc. (KYTX)

      Detailed price information for Kyverna Therapeutics Inc (KYTX-Q) from The Globe and Mail including charting and trades.

      Sep 26The Globe and MailACADKYTX
      Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ)
      Sep 25Seeking AlphaACAD
      Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says

      Acadia Pharmaceuticals' (ACAD) favorable risk-reward remains intact despite remlifanserin narrowly m

      Sep 25Yahoo FinanceACAD
      Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss

      Acadia hopes to become one of the first companies to secure approval for a therapy specifically indicated for ADP.

      Sep 25Yahoo FinanceACAD
      Needham cuts Acadia Pharmaceuticals stock price target on trial results
      Sep 25Investing.comACAD
      Deutsche Bank Lowers Price Target on ACADIA Pharmaceuticals to $31 From $38, Keeps Buy Rating

      ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $32.37, a

      Sep 25Yahoo FinanceACAD
      Citizens cuts Acadia Pharmaceuticals stock price target on trial miss
      Sep 25Investing.comACAD
      ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets

      Acadia's latest trial update has put the spotlight on remlifanserin's development path, prompting analysts to reassess its near-term prospects and valuation.

      Sep 25Yahoo FinanceACAD
      ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13%

      ACADIA Pharmaceuticals (NASDAQ:ACAD) fell for a fifth consecutive day on Thursday, shedding 12.78 percent to close at $22.18 apiece, after earning a sell recommendation from Goldman Sachs. In its market note, the investment firm reiterated its sell recommendation and $17 price target on the stock after missing its primary endpoint in its phase 2 study […]

      Sep 25Yahoo FinanceACAD

      This is the newest page. Registered accounts read further back.